脊柱关节炎类（SpA）疾病，如包括强直性脊柱关节炎（AS）在内的轴索性脊柱关节炎（axSpA）和包括银屑病（PsA）在内的银屑性关节炎（PsA），是一种慢性免疫介导性疾病，肿瘤坏死因子（TNF）、白细胞介素（IL）-17细胞因子和JAK在其发病机制中起着作用， 针对银屑病、PsA和慢性炎症性肠病，IL-23在其中也扮演着明确的角色。 在这篇综述中，我们将重点介绍生物学药物改变抗风湿药（bDMARD）双特异性IL-17A和IL-17 F抑制剂bimekizumab，以及靶向合成（ts）DMARD、JAK抑制剂（i）filgotinib——用于axSpA治疗的新药。Upadacitinib是另一种JAKi，我们最近对其进行了深入审查，并已在欧洲批准用于axSpA和PsA。与抑制IL-17相比，JAKi也可以在类风湿性关节炎（RA）治疗中发挥作用，而抑制IL-17的药物则不行，但有些效果可能会出现。事实上，包括filgotinib在内的4种JAKi已获批用于RA治疗。已有几项bimekizumab在斑块型银屑病的头对头试验。最后一项展示了bimekizumab的双特异性IL-17A和IL-17 F抑制优于300毫克secukinumab（通常剂量）单纯抑制IL-17A。是否对axSpA和PsA的治疗也是如此，有待确定。

Spondyloarthritides (SpA) such as axial spondyloarthritis (axSpA) including ankylosing spondylitis (AS) and psoriatic arthritis (PsA) including psoriasis are chronic immune-mediated disorders with involvement of tumor necrosis factor (TNF), interleukin (IL)-17 cytokines, and janus kinases (JAK) in their pathogenesis, with IL-23 clearly also playing a role in psoriasis, PsA, and chronic inflammatory bowel diseases.In this narrative review, we focus on a biologic disease modifying anti-rheumatic drug (bDMARD), the bispecific IL-17A and IL-17 F inhibitor bimekizumab, and a targeted synthetic (ts) DMARD, the JAK inhibitor (i) filgotinib - emerging agents for the treatment of axSpA. Upadacitinib, another JAKi that has recently been reviewed intensively by us is already approved for axSpA and PsA in Europe.In contrast to inhibition of IL-17, JAKi also work in rheumatoid arthritis (RA), while agents inhibiting IL-17 are not, even though some effect may be there. Indeed, 4 JAKi including filgotinib are approved for RA. There are several head-to-head trials with bimekizumab in plaque psoriasis. The last one showed that the bispecific inhibition of IL-17A and IL-17 F with bimekizumab may indeed be superior to inhibition of IL-17A alone with 300 mg secukinumab (usual dosage). Whether this is also the case for treatment of axSpA and PsA remains to be shown.